Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105975 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 398
- Enrollment target
NCT01105975 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 398 participants.
The verdict
NCT01105975, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 398 participants
- Enrollment target
Study Summary
The primary purpose of your participation in this study is to help answer the following research question(s) * Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat abnormal fat or cholesterol in blood) improves the blood fat profile more than statins alone. * Whether LY2484595 alone improves blood fats profile compared to sugar pills. * Whether LY2484595 interferes with break down or functioning of statins. * Whether LY2484595 has any side effects that would not support testing it in future studies.
Interventions
- DRUG Rosuvastatin
- DRUG Simvastatin
- DRUG Atorvastatin
- DRUG LY2484595
- DRUG Placebo for LY2484595
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105975
The ClinicalTrials.gov registry entry for NCT01105975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 398 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rosuvastatin is the first listed.
NCT01105975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105975 about?
NCT01105975 is a clinical study titled "A Study of LY2484595 in Patients With High LDL-C or Low HDL-C". The primary purpose of your participation in this study is to help answer the following research question(s) * Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat abnormal fat or cholesterol in blood) improves the blood fat profile...
What is the current status of trial NCT01105975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 398 participants. The study started on 2010-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01105975?
The interventions under investigation include: Rosuvastatin (DRUG), Simvastatin (DRUG), Atorvastatin (DRUG), LY2484595 (DRUG), Placebo for LY2484595 (DRUG).
Who is sponsoring clinical trial NCT01105975?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.